Amer Sami
Saskatchewan Cancer Agency(CA)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial(2012)221 cited
- → HER2-directed therapy: current treatment options for HER2-positive breast cancer(2015)180 cited
- → Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study(2014)171 cited
- → Extrapulmonary small cell cancer(2006)123 cited
- → Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer(2021)58 cited
- → Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study(2010)53 cited
- → Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice(2013)47 cited
- → HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination(2006)39 cited
- → Comparison of the Quality of Life of Patients with Breast or Colon Cancer with an Arm Vein Port (TIVAD) Versus a Peripherally Inserted Central Catheter (PICC)(2021)33 cited
- → Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice(2018)29 cited